Nevertheless, we observed a positive trend in recent studies (from 2020 onward), particularly for RSV, where reporting of costs has become more detailed, with more explanation on methodology and more specification of costs into appropriate categories.
← all excerpts
How well do disease-specific studies and WHO-CHOICE cost estimates align? Example of estimating cost per episode of diarrhoea and respiratory syncytial virus in 128 low-income and middle-income countries.
1
—
—